Related Experiment Video
Updated: Jul 14, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Association study between clinical response to rizatriptan and some candidate genes
Carlo Asuni1, Allesandra Cherchi, Donatella Congiu
1Section of Clinical Pharmacology, Department of Neurosciences B.B. Brodie, University of Galiari, P.O. San Giovanni di Dio, Via Ospedale 46, I-09124 Cagliari, Italy. carloasuni@tiscali.it
Genetic variations influence rizatriptan effectiveness for migraine without aura. The DRD2/NcoI C allele may predict a positive clinical response in migraine patients, aiding personalized treatment strategies.
Area of Science:
- Pharmacogenetics
- Neurology
- Genetics
Background:
- Migraine without aura is a common neurological disorder.
- Rizatriptan is a common medication for acute migraine treatment.
- Individual responses to rizatriptan vary, suggesting a potential genetic component.
Purpose of the Study:
- To investigate genetic differences influencing clinical response to rizatriptan in migraine without aura patients.
- To explore the association of specific gene polymorphisms (HTR1B, MAOA, SLC6A4, DRD2) with rizatriptan efficacy.
Main Methods:
- Fifty unrelated patients with migraine without aura were enrolled.
- Patients were classified as responders or non-responders to rizatriptan.
- Genotyping was performed for polymorphisms in candidate genes, including DRD2/NcoI.
Main Results:
- Thirty-one out of fifty patients (62%) responded to rizatriptan.
- A statistically significant difference in allele (p=0.02) and genotype distribution (p=0.03) of the DRD2/NcoI polymorphism was observed between responders and non-responders.
- The DRD2/NcoI C allele was associated with a positive response to rizatriptan.
Conclusions:
- The DRD2/NcoI polymorphism is significantly associated with rizatriptan response in migraine without aura.
- The DRD2/NcoI C allele may serve as a predictive biomarker for good rizatriptan response.
- These findings support the role of pharmacogenetics in optimizing migraine treatment.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Factors Affecting Drug Response: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...